9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Diabetes Fact Sheet in Korea 2021
Bae, J. H., Han, K.-D., Ko, S.-H., Yang, Y. S., Choi, J. H., Choi, K. M., Kwon, H.-S., Won, K. C., & on Behalf of the Committee of Media-Public Relation of the Korean Diabetes Association (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0106 · Cited by 356
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“78 Recent rigorous scientific studies, specifically randomized controlled trials, have proven that GLP-1RAs consistently offer substantial weight loss advantages beyond the early stages of treat-ment.”
BackgroundMosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306
Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298
Diabetes and Stroke: What Are the Connections?
Mosenzon, O., Cheng, A. Y., Rabinstein, A. A., & Sacco, S. (2023) · Journal of Stroke · doi:10.5853/jos.2022.02306 · Cited by 249
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
“As of 2022, GLP-1RAs have been recommended as fi rst-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Association ’ s Standards of Medical Care in Diabetes (248, 249).”
BackgroundCardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Wang, T.-Y., Wang, R.-F., Bu, Z.-Y., Targher, G., Byrne, C. D., Sun, D.-Q., & Zheng, M.-H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00519-y · Cited by 210
Pullano, S. A., Greco, M., Bianco, M. G., Foti, D., Brunetti, A., & Fiorillo, A. S. (2022) · Theranostics · doi:10.7150/thno.64035 · Cited by 210
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
Rubino, F., Cohen, R. V., Mingrone, G., le Roux, C. W., Mechanick, J. I., Arterburn, D. E., Vidal, J., Alberti, G., Amiel, S. A., Batterham, R. L., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30157-1 · Cited by 174
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Yamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 159
Fishbein, L. M., Rivero, J. D., Else, T., Howe, J. R., Asa, S. L., Cohen, D. L., Dahia, P. L. M., Fraker, D. L., Goodman, K. A., Hope, T. A., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001792 · Cited by 168
Cheng, X., Liu, Y.-M., Li, H., Zhang, X., Lei, F., Qin, J.-J., Chen, Z., Deng, K.-Q., Lin, L., Chen, M.-M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.013 · Cited by 157
Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157
Metformin, Macrophage Dysfunction and Atherosclerosis
Feng, X., Chen, W., Ni, X., Little, P. J., Xu, S., Tang, L., & Weng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682853 · Cited by 164
Giugliano, D., Longo, M., Signoriello, S., Maiorino, M. I., Solerte, B., Chiodini, P., & Esposito, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01474-z · Cited by 153
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152
Saxena, A. R., Frias, J. P., Brown, L. S., Gorman, D. N., Vasas, S., Tsamandouras, N., & Birnbaum, M. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14493 · Cited by 149
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 171
Kobori, T., Onishi, Y., Yoshida, Y., Tahara, T., Kikuchi, T., Kubota, T., Iwamoto, M., Sawada, T., Kobayashi, R., Fujiwara, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14005 · Cited by 144
The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415743 · Cited by 156
Kwan, T. W., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., Deedwania, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 133
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15058 · Cited by 131
The emergence of obesity in type 1 diabetes
Kueh, M. T. W., Chew, N. W. S., Al-Ozairi, E., & le Roux, C. W. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01429-8 · Cited by 111
“While the latest guidelines recommend SGLT2 inhibitors and GLP1-RA for adults with T2D and established CVD, [126, 127] an analysis of out-of-pocket costs in the USA found T a b l e 2 .”
BackgroundThe psychophysiology of anxiety.
LADER, M. H. (1983) · PubMed · Cited by 133
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease
Chakaroun, R., Olsson, L. M., & Bäckhed, F. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00771-0 · Cited by 139
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
Aras, M., Tchang, B. G., & Pape, J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.008 · Cited by 108
Wang, C., Yen, H., Lu, W., Ho, H.-H., Lin, W., Kuo, Y., Huang, Y.-Y., Tsai, S., & Lin, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.754401 · Cited by 125
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 139
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.036 · Cited by 121
Adverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106
Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18306 · Cited by 106
“Glucose-lowering drugs (GLDs) are a cornerstone for controlling diabetes and ameliorating end-organ damage.(10) Preclinical studies have suggested that newer GLDs, including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT2) inhib…”
BackgroundManagement of diabetic ketoacidosis in adults: A narrative review
Elzouki, A.-N. Y., & Eledrisi, M. S. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_478_19 · Cited by 120
Management of Obesity in Adults with CKD
Friedman, A. N., Kaplan, L. M., le Roux, C. W., & Schauer, P. R. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101472 · Cited by 94
Di, X., Liu, S., Xiang, L., & Jin, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1116224 · Cited by 105
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Beyond glucose control and weight reduction, GLP1RAs were shown to reduce cardiovascular morbidity and mortality and are therefore strongly recommended in early lines of diabetic therapy [3, 4].”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14765 · Cited by 86
Ueki, K., Sasako, T., Okazaki, Y., Miyake, K., Nangaku, M., Ohashi, Y., Noda, M., & Kadowaki, T. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.012 · Cited by 94
Wu, C., Ouk, M., Wong, Y. Y., Anita, N. Z., Edwards, J. D., Yang, P., Shah, B. R., Herrmann, N., Lanctôt, K. L., Kapral, M. K., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12161 · Cited by 91
McPherson, S., Armstrong, M. J., Cobbold, J., Corless, L., Anstee, Q. M., Aspinall, R., Barclay, S. T., Brennan, P. N., Cacciottolo, T. M., Goldin, R. D., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00061-9 · Cited by 105
Tsai, S., Yang, C., Liu, W.-J., & Lee, C.-L. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101934 · Cited by 98
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Jardine, M., Kahleová, H., Levin, S., Ali, Z., Trapp, C., & Barnard, N. D. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab063 · Cited by 97
Neves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D., Packer, M., Zannad, F., Leite‐Moreira, A., & Ferreira, J. P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 80
“In randomized controlled trials (RCTs), GLP1RAs decreased the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) with a high cardiovascular risk,(2) and current guidelines for treatment of T2D propose GLP1RAs as a preferential class for those patients at high risk of atherosclero…”
BackgroundLee, E. Y., Cha, S.-A., Yun, J.-S., Lim, S.-Y., Lee, J.-H., Ahn, Y.-B., Yoon, K.-H., Hyun, M. K., & Ko, S.-H. (2022) · Journal of Medical Internet Research · doi:10.2196/37430 · Cited by 83
“The main goal of diabetes management is to maintain glycemic control within the target range, which is often accomplished through lifestyle modification and the self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes mellitus (T2DM) [2,3].”
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Philis‐Tsimikas, A., BAJAJ, H. S., Begtrup, K., Cailleteau, R., Gowda, A., Lingvay, I., Mathieu, C., Russell-Jones, D. L., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14871 · Cited by 83
“the disease progresses.(1) However, initiating and optimizing basal insulin therapy in T2D can be challenging owing to many factors, resulting in poor attainment of recommended glycaemic targets.”
BackgroundLuo, J., Feldman, R., Callaway Kim, K., Rothenberger, S., Korytkowski, M., Hernandez, I., & Gellad, W. F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.17886 · Cited by 82
Sánchez-Fructuoso, A. I., Raba, A. B., Banegas‐Deras, E. J., Vigara, L. A., Valero, R., Esteve, A. F., Vega, L. L. C., Gavela, E., González, E., Coronado, P. S., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad007 · Cited by 82
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Healthcare AI Treatment Decision Support: Design Principles to Enhance Clinician Adoption and Trust
Burgess, E. R., Jankovic, I., Austin, M., Cai, N., Kapuścińska, A., Currie, S., Overhage, J. M., Poole, E. S., & Kaye, J. (2023) · Proceedings of the 2023 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3544548.3581251 · Cited by 65
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
Asl, L. H., Liepnieks, J. J., Uemichi, T., Rebibou, J.-M., Justrabo, E., Droz, D., Mousson, C., Chalopin, J. M., Benson, M. D., Delpech, M., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4799 · Cited by 76
Rajan, N., Duggan, E. W., Abdelmalak, B., Butz, S. F., Rodriguez, L. V., Vann, M. A., & Joshi, G. P. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006791 · Cited by 85
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02753-6 · Cited by 74
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 65
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
(2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00240-0 · Cited by 67
Yang, W., Zhu, D., Gan, S., Dong, X., Su, J.-P., Li, W., Jiang, H., Zhao, W., Yao, M., Song, W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01803-5 · Cited by 79
Svanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 71
The Role of Obesity and Diabetes in Dementia
Selman, A., Burns, S., Reddy, A. P., Culberson, J. W., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169267 · Cited by 80
Persson, F., Bain, S. C., Mosenzon, O., Heerspink, H. J. L., Mann, J. F. E., Pratley, R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1622 · Cited by 71
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
Wang, K. M., & Isom, R. T. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.006 · Cited by 67
Nersessian, R. S. F., da Silva, L. M., Carvalho, M. A. S., Silveira, S. Q., Abib, A. C. V., Bellicieri, F. N., Lima, H. O., Ho, A. M. ‐., Anjos, G. S., & Mizubuti, G. B. (2024) · Anaesthesia · doi:10.1111/anae.16454 · Cited by 69
“In recent years, semaglutide has gained signi fi cant popularity due to its convenient once-weekly administration, promotion of weight loss [2, 3] and organ protection in patients with [4] and without [3, 5 – 7] diabetes.”
Essien, U. R., Singh, B., Swabe, G., Johnson, A. E., Eberly, L. A., Wadhera, R. K., Breathett, K., Vaduganathan, M., & Magnani, J. W. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.16290 · Cited by 69
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67
Physiological Closed-Loop Control (PCLC) Systems: Review of a Modern Frontier in Automation
Khodaei, M. J., Candelino, N. W., Mehrvarz, A., & Jalili, N. (2020) · IEEE Access · doi:10.1109/access.2020.2968440 · Cited by 72
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
“21 Our findings are consistent with those of previous evidence from earlier RCTs 8,25 and meta-analyses, 9,10 which showed that incretin-based drugs do not pose a higher risk of thyroid cancer.”
ResultHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 80
Frías, J. P., Chien, J. Y., Zhang, Q., Chigutsa, E., Landschulz, W. H., Syring, K. E., Wullenweber, P. K., Haupt, A., & KAZDA, C. M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00388-6 · Cited by 71
Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63
Ramsey, D. J., Makwana, B., Dani, S. S., Patel, M., Panchal, K., Shah, J., Khadke, S., Kumar, A., Patel, T., Kosiborod, M. N., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26321 · Cited by 63
Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials
Kramer, C. K., Retnakaran, R. R., & Zinman, B. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.014 · Cited by 75
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
Daza-Arnedo, R., Rico-Fontalvo, J.-E., Pájaro-Galvis, N., Leal-Martínez, V., Abuabara-Franco, E., Raad-Sarabia, M., Montejo-Hernández, J. D., Cardona-Blanco, M., Cabrales, J., Uparella-Gulfo, I., et al. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.07.007 · Cited by 68
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.